A recent study has found that the migraine drug fremanezumab can significantly reduce the symptoms of both migraines and ...

The FDA has approved a dihydroergotamine-based nasal powder for the acute treatment of migraine with or without aura in ...

CGRP antagonists are a new class of drugs designed to prevent migraine headaches by targeting a key molecule involved in pain transmission. Calcitonin gene-related peptide (CGRP) monoclonal ...

A migraine drug has shown to significantly reduce symptoms of depression in patients—the first trial to show improvements in ...

The American College of Physicians (ACP) has developed new recommendations for treatment of acute episodic migraines in ...

Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

The software-based intervention aims to reduce brain hypersensitivity in patients with migraine by modulating responses to environmental and internal stimuli through a 12-week program.

Despite opioids continuing its hold as the most-prescribed drug class in workers' compensation, migraine medications and topicals are gaining ground as alternatives to pain management, according to ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

A migraine drug has shown to significantly reduce symptoms of depression in patients -- the first trial to show improvements in both the conditions using a single drug, researchers said.